EMERYVILLE, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biotechnology company focused on the topical, anti-infective market, today announced that Ron Najafi, Ph.D., Chairman and CEO of NovaBay Pharmaceuticals, will present a corporate and clinical update at the 8th Annual JMP Securities Healthcare Conference, held July 9-10, 2013 in New York City. Ron Najafi and Tom Paulson, Chief Financial Officer of NovaBay, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
|Event:||JMP Securities Healthcare Conference|
|Date:||Wednesday, July 10, 2013|
|Time:||4:00 pm EDT|
|Place:||New York City|
To access the live audio webcast of this presentation, please log on through a link located in the News & Events section of NovaBay's website at http://novabay.com/investors/events . A replay of the webcast will be available one hour after the conclusion of the live event.
About NovaBay Pharmaceuticals, Inc.Going Beyond Antibiotics NovaBay Pharmaceuticals is a biotechnology company focused on addressing the large unmet therapeutic needs of the global, topical anti-infective market with auriclosene. The Company's four core business units – DermaBay, UroBay, EyeBay and MediBay – are developing products in dermatology, urology, ophthalmology, and wound care areas.
|Stay informed on NovaBay's progress:|
|Like us on Facebook|
|Follow us on Twitter|
|Connect with NovaBay on LinkedIn|
|Join us on Google+|
|Visit NovaBay's Website|
CONTACT: NovaBay Pharmaceuticals Contacts Thomas J. Paulson Chief Financial Officer 510-899-8809 email@example.com Ana Kapor Director, Investor Relations and Corporate Communications NovaBay Pharmaceuticals, Inc. 510-899-8889 firstname.lastname@example.org
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts